BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heebøll S, Thomsen KL, Pedersen SB, Vilstrup H, George J, Grønbæk H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol 2014; 6(4): 188-198 [PMID: 24799987 DOI: 10.4254/wjh.v6.i4.188] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Scherzberg M, Kiehl A, Zivkovic A, Stark H, Stein J, Fürst R, Steinhilber D, Ulrich-rückert S. Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action. Toxicology and Applied Pharmacology 2015;287:67-76. [DOI: 10.1016/j.taap.2015.05.020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
2 Grujic-milanovic J, Miloradovic Z, Jovovic D, Jacevic V, Milosavljevic I, Milanovic SD, Mihailovic-stanojevic N. The red wine polyphenol, resveratrol improves hemodynamics, oxidative defence and aortal structure in essential and malignant hypertension. Journal of Functional Foods 2017;34:266-76. [DOI: 10.1016/j.jff.2017.04.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
3 Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, Gupta SC. Health benefits of resveratrol: Evidence from clinical studies. Med Res Rev 2019;39:1851-91. [PMID: 30741437 DOI: 10.1002/med.21565] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 36.7] [Reference Citation Analysis]
4 Gwaltney-brant SM. Nutraceuticals in Hepatic Diseases. Nutraceuticals. Elsevier; 2016. pp. 87-99. [DOI: 10.1016/b978-0-12-802147-7.00007-3] [Cited by in Crossref: 9] [Article Influence: 1.5] [Reference Citation Analysis]
5 Kang JH, Choung SY. Protective effects of resveratrol and its analogs on age-related macular degeneration in vitro. Arch Pharm Res 2016;39:1703-15. [PMID: 27659166 DOI: 10.1007/s12272-016-0839-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
6 Korsholm AS, Kjær TN, Ornstrup MJ, Pedersen SB. Comprehensive Metabolomic Analysis in Blood, Urine, Fat, and Muscle in Men with Metabolic Syndrome: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Resveratrol after Four Months' Treatment. Int J Mol Sci 2017;18:E554. [PMID: 28273841 DOI: 10.3390/ijms18030554] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
7 Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
8 Dolezelova E, Prasnicka A, Cermanova J, Carazo A, Hyrsova L, Hroch M, Mokry J, Adamcova M, Mrkvicova A, Pavek P, Micuda S. Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World J Gastroenterol 2017; 23(43): 7678-7692 [PMID: 29209109 DOI: 10.3748/wjg.v23.i43.7678] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Badi RM, Mostafa DG, Khaleel EF, Satti HH. Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. Clin Exp Pharmacol Physiol 2019;46:545-55. [PMID: 30773673 DOI: 10.1111/1440-1681.13074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
10 Khaleel EF, Abdel-aleem GA, Mostafa DG. Resveratrol improves high-fat diet induced fatty liver and insulin resistance by concomitantly inhibiting proteolytic cleavage of sterol regulatory element-binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption. Can J Physiol Pharmacol 2018;96:145-57. [DOI: 10.1139/cjpp-2017-0001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
11 Heebøll S, El-Houri RB, Hellberg YE, Haldrup D, Pedersen SB, Jessen N, Christensen LP, Grønbaek H. Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. J Gastroenterol Hepatol 2016;31:668-75. [PMID: 26312773 DOI: 10.1111/jgh.13151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
12 Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, Chen SH, Zhang T, Zhou X, Zou D. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res. 2015;59:1443-1457. [PMID: 25943029 DOI: 10.1002/mnfr.201500016] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 13.4] [Reference Citation Analysis]
13 Cheng K, Song Z, Zhang H, Li S, Wang C, Zhang L, Wang T. The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression. Med Mol Morphol 2019;52:187-97. [PMID: 30673851 DOI: 10.1007/s00795-019-00216-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
14 Heimesaat MM, Mousavi S, Escher U, Lobo de Sá FD, Peh E, Schulzke JD, Kittler S, Bücker R, Bereswill S. Resveratrol Alleviates Acute Campylobacter jejuni Induced Enterocolitis in a Preclinical Murine Intervention Study. Microorganisms 2020;8:E1858. [PMID: 33255723 DOI: 10.3390/microorganisms8121858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bønløkke Pedersen S, Grønbæk H. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 2016;51:456-64. [PMID: 26784973 DOI: 10.3109/00365521.2015.1107620] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 12.2] [Reference Citation Analysis]
16 Liu C, Liao JZ, Li PY. Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(11): 1964-1973 [PMID: 28373762 DOI: 10.3748/wjg.v23.i11.1964] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
17 Charytoniuk T, Harasim-symbor E, Polak A, Drygalski K, Berk K, Chabowski A, Konstantynowicz-nowicka K. Influence of Resveratrol on Sphingolipid Metabolism in Hepatocellular Carcinoma Cells in Lipid Overload State. ACAMC 2019;19:121-9. [DOI: 10.2174/1871520619666181224161255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Ricker MA, Haas WC. Anti-Inflammatory Diet in Clinical Practice: A Review. Nutr Clin Pract 2017;32:318-25. [DOI: 10.1177/0884533617700353] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 7.2] [Reference Citation Analysis]
19 Bruckbauer A, Banerjee J, Fu L, Li F, Cao Q, Cui X, Wu R, Shi H, Xue B, Zemel MB. A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice. Int J Hepatol 2016;2016:9185987. [PMID: 28042486 DOI: 10.1155/2016/9185987] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
20 Deng H, Mi MT. Resveratrol Attenuates Aβ25-35 Caused Neurotoxicity by Inducing Autophagy Through the TyrRS-PARP1-SIRT1 Signaling Pathway. Neurochem Res 2016;41:2367-79. [PMID: 27180189 DOI: 10.1007/s11064-016-1950-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
21 Asghari S, Asghari-jafarabadi M, Somi M, Ghavami S, Rafraf M. Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Journal of the American College of Nutrition 2017;37:223-33. [DOI: 10.1080/07315724.2017.1392264] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
22 Trepiana J, Milton-Laskibar I, Gómez-Zorita S, Eseberri I, González M, Fernández-Quintela A, Portillo MP. Involvement of 5'-Activated Protein Kinase (AMPK) in the Effects of Resveratrol on Liver Steatosis. Int J Mol Sci 2018;19:E3473. [PMID: 30400630 DOI: 10.3390/ijms19113473] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
23 Pennisi M, Bertino G, Gagliano C, Malaguarnera M, Bella R, Borzì AM, Madeddu R, Drago F, Malaguarnera G. Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. Nutrients 2017;9:E897. [PMID: 28820468 DOI: 10.3390/nu9080897] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
24 Liu FC, Tsai YF, Tsai HI, Yu HP. Anti-Inflammatory and Organ-Protective Effects of Resveratrol in Trauma-Hemorrhagic Injury. Mediators Inflamm 2015;2015:643763. [PMID: 26273141 DOI: 10.1155/2015/643763] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
25 de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1137-44. [DOI: 10.1016/j.bbadis.2014.11.012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 11.7] [Reference Citation Analysis]
26 Heebøll S, Thomsen KL, Clouston A, Sundelin EI, Radko Y, Christensen LP, Ramezani-moghadam M, Kreutzfeldt M, Pedersen SB, Jessen N, Hebbard L, George J, Grønbæk H. Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research 2015;95-96:34-41. [DOI: 10.1016/j.phrs.2015.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
27 Christenson J, Whitby SJ, Mellor D, Thomas J, McKune A, Roach PD, Naumovski N. The Effects of Resveratrol Supplementation in Overweight and Obese Humans: A Systematic Review of Randomized Trials. Metab Syndr Relat Disord 2016;14:323-33. [PMID: 27379440 DOI: 10.1089/met.2016.0035] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
28 Liu J, Xu Y, Hu Y, Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64:380-390. [PMID: 25516477 DOI: 10.1016/j.metabol.2014.11.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 7.9] [Reference Citation Analysis]
29 Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol 2015; 7(2): 204-212 [PMID: 25729475 DOI: 10.4254/wjh.v7.i2.204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
30 Kim JW, Lee YJ, You YH, Moon MK, Yoon KH, Ahn YB, Ko SH. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem 2018. [PMID: 30474134 DOI: 10.1002/jcb.28141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
31 Trepiana J, Krisa S, Renouf E, Portillo MP. Resveratrol Metabolites Are Able to Reduce Steatosis in Cultured Hepatocytes. Pharmaceuticals (Basel) 2020;13:E285. [PMID: 33008087 DOI: 10.3390/ph13100285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cole LK, Mejia EM, Sparagna GC, Vandel M, Xiang B, Han X, Dedousis N, Kaufman BA, Dolinsky VW, Hatch GM. Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy. J Mol Cell Cardiol 2020;144:24-34. [PMID: 32418915 DOI: 10.1016/j.yjmcc.2020.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
33 McGill MR, Du K, Weemhoff JL, Jaeschke H. Critical review of resveratrol in xenobiotic-induced hepatotoxicity. Food Chem Toxicol 2015;86:309-18. [PMID: 26561740 DOI: 10.1016/j.fct.2015.11.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
34 Pan QR, Ren YL, Liu WX, Hu YJ, Zheng JS, Xu Y, Wang G. Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. Nutr Res 2015;35:576-84. [PMID: 26055348 DOI: 10.1016/j.nutres.2015.05.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]